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Background and Objective
Setting and Methods
Main Outcome Measures
Clinical profile and treatment discontinuation in a 
tuberculosis control state programme in Brazil: 
preliminary results from SINAN database
Results
Conclusions
• Discontinuing tuberculosis (TB) treatment can leave 
patients infectious and contributes to the emergence of 
resistance. 
• This study aimed to describe the clinical profile and cure 
and discontinuation rates of TB patients enrolled in the 
Pernambuco Tuberculosis Control Programme (PECT).
• Study was conducted in three sites in Recife, in the state 
of Pernambuco, Brazil.
• Data were extracted from the Notifiable Diseases 
Information System (SINAN) for PECT outpatients 
(n=440). Sociodemographic data were available for sites 
A and B only.
• Data collection period: 01/2012 to 12/2014 
• Analysis was performed with Action for Excel; there is on-
going analysis to further explore differences across sites. 
• Ethical approval was granted.
• Clinical form of the disease 
• HIV testing 
• New cases
• Cure 
• Treatment discontinuation.
Sociodemographic data (sites A + B) 
Male patients: 70%
Age 20 – 49 years: 60.5%
Low education level: 46%
Overall, most common clinical 
presentation:  Pulmonary TB
Overall* 
New cases: 78.4%
Recurrence: 5.9      
Enrolment after 
discontinuation 10.9%
Rates for cure
Site A: 59.1	%	
Site B: 28.95%	
Site C: 16.6%	
Treatment Discontinuation
Site A: 21.2	%
Site B: 24.9%	
Site C: 4.3%
HIV testing
Seropositive: 27.73%, 
Seronegative: 37.27%,
Test not performed  35% 
TB-related mortality
ranged from 0 (site C) to 
5.4%  (site B)
8	general	practice	
units	+	1	polyclinic
1	hospital	for	
medium-complexity		
patients	
1	hospital	for	
high-complexity	
patients
SITE	A SITE	B SITE	C
• Site B presented the highest rate of treatment discontinuation, TB-
related mortality and the lowest rate of enrolment after treatment 
discontinuation. Patients co-infected with TB and HIV are firstly 
referred to this site, which may explain this finding.
• Findings may help managers allocating resources and clinical 
pharmacists in planning their interventions.
• More intensive interventions in TB patients are necessary, such as 
pharmaceutical care programmes.
* The remainder percentage pertains to patients’ transfer and changes in diagnosis. 
